Omalizumab in Severe and Refractory Solar Urticaria — XOLUS  

Solar Urticaria Clinical Trial

Official title: Phase 2 Multicentric Study Evaluating the Efficacy of Omalizumab in Idiopathic Severe and Refractory Solar Urticaria

Status Completed

Clinical Trial Summary

Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on quality of life. New treatment options are warranted. The investigators aim to test the efficacy and the safety of omalizumab, an anti-IgE antibody recently approved in chronic spontaneous urticaria, in this setting.

Clinical Trial Description

This is an open-labelled multicentric phase II study testing the efficacy and the safety of omalizumab 300 mg (W0, W4 and W8) in patients affected with severe and refractory solar urticaria. ;

Related Conditions & MeSH terms

• Solar Urticaria
• Urticaria

• NCT number: NCT02262130
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Besancon
• Status: Completed
• Phase: Phase 2
• Start date: September 30, 2014
• Completion date: September 29, 2015